Overview

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and effectiveness of using Iodine-131 Anti-B1 Antibody for the treatment of patients with large B-cell non-Hodgkin's lymphoma (NHL) who have achieved a response following 6-8 cycles of CHOP therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Corixa Corporation

Treatments:

Antibodies
Antibodies, Monoclonal
Cadexomer iodine
Immunoglobulins
Iodine
Iodine-131 anti-B1 antibody
Tositumomab I-131